HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Advanced Medical Equipment & Technology

Delayed OTC Markets Other stock markets 20:46:45 23/05/2024 BST			5-day change	1st Jan Change
0.0025 ^USD	-.--%		-.--%	+92.31%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

HTG Molecular Diagnostics, Inc. Announces Management Changes, Effective March 31, 2019

January 30, 2019 at 09:01 pm

On January 14, 2019, the board of directors of HTG Molecular Diagnostics, Inc. appointed John L. Lubniewski as the Chief Executive Officer and designated Timothy B. Johnson as Executive Chairman of the Board, each effective March 31, 2019. Mr. Johnson's service as Executive Chairman of the Board, effective as of the Effective Date.

Latest news about HTG Molecular Diagnostics, Inc.

Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	25/08/23	CI
Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	16/08/23	CI
Trustee/Examiner Appointed Under Chapter 11 for HTG Molecular Diagnostics, Inc.	21/07/23	CI
HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index	14/06/23	CI
HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index	08/06/23	CI
Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer	05/06/23	CI
HTG Molecular Diagnostics, Inc. Filed for Bankruptcy	05/06/23	CI
HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization	18/05/23	CI
Top Premarket Gainers	17/05/23	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
HC Wainwright Adjusts Price Target on HTG Molecular Diagnostics to $6 From $15, Maintains Buy Rating	03/04/23	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
HTG Molecular Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Certain Warrants of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	21/02/23	CI
Certain Restricted Stock Units of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	21/02/23	CI
Certain Stock Options of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	21/02/23	CI
Certain Common Stock of HTG Molecular Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2023.	21/02/23	CI
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event	09/01/23	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022	06/01/23	CI
China's Move to End COVID Quarantine for Inbound Travelers Sparks Premarket Gains for US Equities	27/12/22	MT
Top Premarket Gainers	27/12/22	MT
HTG Molecular Diagnostics to Begin Trading on Split-Adjusted Basis on Wednesday	20/12/22	MT
Transcript : HTG Molecular Diagnostics, Inc. - Special Call	13/12/22
Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	12/12/22	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	12/12/22	MT

Chart HTG Molecular Diagnostics, Inc.

Duration

Period

More charts

Company Profile

HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.

Sector

Advanced Medical Equipment & Technology

Calendar

07/05/2025 - Q1 2025 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
HTG MOLECULAR DIAGNOSTICS, INC.	+92.31%	5.54K
QUIDELORTHO CORPORATION	-39.82%	3.01B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+20.05%	1.9B
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-9.59%	1.51B
BIOTAGE AB	+31.71%	1.43B
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-18.07%	944M
CONTEC MEDICAL SYSTEMS CO.,LTD	-27.78%	827M
REVENIO GROUP OYJ	+3.31%	819M
VAREX IMAGING CORPORATION	-23.66%	650M
CELLAVISION AB	+24.29%	618M

Medical Diagnostic & Testing Equipment